Meta-analysis of a partially hydrolysed 100%-whey infant formula vs. extensively hydrolysed infant formulas in the prevention of atopic dermatitis
- 6 October 2010
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 26 (11) , 2599-2606
Abstract
This study presents previously unpublished point and cumulative incidence rates and relative risks (RRs) for comparing a partially hydrolysed 100% whey-based infant formula, NAN-HA (PHF-W) to extensively hydrolysed whey- (EHF-Whey) or casein-based (EHF-Casein) infant formulas in the prevention of atopic dermatitis (AD) in infants who cannot be breastfed exclusively. It also outlines methods to convert the above-mentioned data as well as data comparing PHF-W to cows’ milk formula (SF) into inputs to be applied to a pharmacoeconomic model. The incidence rates and RRs were obtained from a meta-analysis which analysed efficacy for PHF-W vs. EHF but did not present those. It took into consideration any relevant randomized controlled trial which compared the use of PHF-W with SF or EHF for the prevention of allergies. The primary outcomes of interest were the incidence, cumulative incidence and period prevalence of allergic manifestations and of AD in particular. Fifteen studies had been included for analysis of which six studies explored PHF-W vs. EHF. These results and PHF-W vs. SF data were adapted for inputs into a pharmacoeconomic model which used a spreadsheet decision-analytic economic model based on 3-month cycles to explore the cost-effectiveness of PHF-W vs. SF and EHF. Weights were applied to the incidence rates and RRs for each reported time period which were then adapted into 3-month indicators. This meta-analysis for PHF-W (557 patients) vs. EHF-Whey (559 patients) yielded RR of 0.75 (0.54, 1.05) and 0.80 (0.63, 1.02) at 0–12 months and at 0–36 months, respectively. Corresponding RRs for PHF-W vs. EHF-Casein (580 patients) were 1.06 (0.74, 1.53) at 0–12 months and 1.13 (0.87, 1.47) at 0–36 months. It appears that the efficacy of PHF-W falls within the range of that of both EHF formulas (whey and casein) and allows the application of these results in a pharmacoeconomic model.Keywords
This publication has 12 references indexed in Scilit:
- Economic evaluation of a 100% whey-based, partially hydrolysed formula in the prevention of atopic dermatitis among French childrenCurrent Medical Research and Opinion, 2010
- Meta-analysis of the evidence for a partially hydrolyzed 100% whey formula for the prevention of allergic diseasesCurrent Medical Research and Opinion, 2009
- Preventive effect of hydrolyzed infant formulas persists until age 6 years: Long-term results from the German Infant Nutritional Intervention Study (GINI)Journal of Allergy and Clinical Immunology, 2008
- Certain hydrolyzed formulas reduce the incidence of atopic dermatitis but not that of asthma: Three-year results of the German Infant Nutritional Intervention StudyJournal of Allergy and Clinical Immunology, 2007
- Use of hypoallergenic formula in the prevention of atopic disease among Asian childrenJournal of Paediatrics and Child Health, 2002
- Comparison of a partially hydrolyzed infant formula with two extensively hydrolyzed formulas for allergy prevention:A prospective, randomized studyPediatric Allergy and Immunology, 2000
- Influence of breast milk, soy or two hydrolyzed formulas on the development of allergic manifestations in infants at riskNutrition Research, 1998
- Effects of a dietary and environmental prevention programme on the incidence of allergic symptoms in high atopic risk infants: three years follow‐upActa Paediatrica, 1996
- The long-term effect of a partial whey hydrolysate formula on the prophylaxis of atopic diseaseEuropean Journal of Pediatrics, 1995
- Preliminary data on a field study with a new hypo-allergic formulaEuropean Journal of Pediatrics, 1988